Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market December 4, 2025 – 7:45 a.m. CET Regulated information Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market Mortsel, Belgium – December 4, 2025 – 7:45 a.m. CET Agfa today announced that it plans to implement additional measures to adjust the cost base of its traditional film activities to the accelerated global market decline. These measures are an extension to the plan that was announced in Novem...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt 4 december 2025 – 7:45 uur CET Gereglementeerde informatie Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt Mortsel, België – 4 december 2025 – 7u45 Agfa kondigde vandaag aan dat het van plan is bijkomende maatregelen te nemen om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de versnelde achteruitgang van de wereldwijde markten. Deze...
This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB
Biotalys announces it has received regulatory approval for Evoca (its first Biofungicide) from EPA, the US Environmental Protection Agency. We maintain our Buy rating. Recall we already upped our TP from €6.1 to €7.5 end October 2025 when EPA issued proposed registration decision for Evoca. At that moment, the EPA also posted a final rule exempting Evoca's active ingredient residues on treated crops from tolerance requirements. Positive is that no maximum residue limits will apply given Evoca's ...
Adecco: Introduces the agility advantage to grow, adapt and lead in the intelligent era. Belgian telcos: DAZN announces immediatele end for Belgian football broadcasting. CMB.TECH: Good 3Q thanks to its tankers. D'Ieteren: CFO buys more shares, State Farm seeks 6% California Auto Rate cut. Staffing: Belgium October Temp volume stable at -3.4% YoY despite tougher comps.
Two Directors at Deceuninck NV bought 8,550 shares at between 2.030EUR and 2.050EUR. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
After three quarters, Agfa's 9M25 “Mature Business” (Radiology and Film DPC) sales dropped -6.4% y/y, driven by the accelerating medical film decline. While its “Growth Engines” (HealthCare IT, Digital Printing Solutions, Green Hydrogen Solutions) are intended to offset this, they also fell -0.9% y/y in the first nine months. We remain cautious (Hold; €1.0 Target Price) until strategic measures deliver and growth engines regain momentum.
Agfa's 3Q25 continued decline in medical film was even stronger than expected (€ 257m 3Q25 sales vs € 275m KBCS & CSS). Although the growth in cloud/SaaS in HealthCare IT all the divisions were below our and CSS forecasts as well on top-line as on REBIT-margins. The increase in Digital Printing & Chemicals was not sufficiently offsetting the impact from the decline in medical film and from cloud transition in HealthCare IT. Despite good cost control, REBIT decreased to -4m, mainly due to the d...
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Regulated information November 13, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Group performance: Top line decrease of 7.1% (-4.7% currency comparable): increase in Digital Printing & Chemicals not sufficiently offsetting impact from decline in medical...
De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Gereglementeerde informatie 13 november 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Groepsprestatie: Omzetdaling van 7,1% (-4.7% zonder wisselkoerseffecten): stijging ...
Adyen: CMD press release; strong growth for the years ahead. Heijmans: Nice bolt-on! Kendrion: Hitting a 15.5% EBITDA margin in 3Q25. Staffing Sector: French staffing: September trend weaker but October outlook slightly better despite tougher comps. TKH Group: Weak 3Q EBITA, keeps FY outlook
Adecco: 3Q25 strong beat; outlook 4Q25 seems in line. Air France-KLM: Bit light but outlook unchanged. ArcelorMittal: In line 3Q25, supportive medium-term outlook. AMG: 3Q25 EBITDA beats by 5%, ‘only' modest FY guidance increase might disappoint. BAM Group: Maintains outlook as expected. CTP: Guidance at the lower end due to a missed deal in Romania. Strong operational trends continued. IMCD: 3Q showed pressure on gross margin. Kinepolis: US peer AMC; better revenues and EBITDA in ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.